Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In rough trial comparisons, Retatrutides TRIUMPH-1 data shows around 28.3% mean weight loss at 80 weeks on the 12 mg dose, with up to 30.3% at 104 weeks in a select extension population
A licensed prescriber (MD, DO, NP, or PA depending on state scope) must attest that the patient has no contraindications to GLP-1 therapy, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
Most users run 812 week cycles , though some protocols extend to 1620 weeks when used for longevity or injury repair
These markers track metabolic response and ensure safe dose escalation
NASH, Non-alcoholic steatohepatitis
It contains the active ingredient semaglutide, which belongs to a class of drugs known as GLP-1 receptor agonists
